In September 2018, the Pharmacy and Therapeutics Committee approved a new protocol for Emergent Vitamin K Antagonist (Warfarin) reversal via fixed dose Kcentra (PCC). We will go live with this protocol on January 22, 2019. |
Read more >>
Thank you, Paul Veregge, M.D.
CIO/CMIO
University of Mississippi Medical Center
Helpful Links: DIS Newsletter Archive,
|